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Irreversible MMP-9 inhibition is considered a signiﬁcant therapeutic goal in inﬂammatory, vascular
and tumour pathology. We report that divalent cation chelators Alendronate and EDTA not only
directly inhibited MMP-9 but also promoted irreversible plasmin-mediated MMP-9 inactivation by
exposing cryptic plasmin-degradation sites within the MMP-9 catalytic-domain and producing an
inhibitory hemopexin–domain fragment. This effect was also observed using MDA-MB-231 breast
cancer cells, which activated exogenous plasminogen to degrade endogenous proMMP-9 in the pres-
ence of Alendronate or EDTA. Degradation-mediated inactivation of proMMP-9 occurred in the
absence of transient activation, attesting to the incapacity of plasmin to directly activate proM-
MP-9 and direct MMP-9 inhibition by Alendronate and EDTA. Our study provides a novel rational
for therapeutic Alendronate use in MMP-9-dependent pathology characterised by plasminogen
activation.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Matrix metalloproteinases (MMPs) and the plasmin generating
system form part of an interactive proteolytic cascade that is in-
volved in inﬂammatory, vascular and tumour pathology [1–6].
Plasmin generated from plasminogen by the action of plasminogen
activators has been shown to activate selective MMPs, which in
turn activate other MMPs, to amplify and diversify proteolytic
activity [7–9]. This interactive proteolytic cascade exhibits nega-
tive feedback regulation, characterised by autocatalytic MMP and
plasmin inactivation and the capacity of MMPs such as MMP-3
and MMP-9 to degrade plasmin to inhibitory fragments, including
angiostatin [7,10,11].
Amongst the MMP family, MMP-9 is considered to play a critical
role in inﬂammatory, vascular and tumour pathology, has been
directly implicated in aberrant extracellular matrix remodelling
associated with diabetes, kidney and destructive bone disease, tu-
mour associated vasculargenesis, angiogenesis, invasion andchemical Societies. Published by E
-9; TIMP, tissue inhibitor of
tate; EDTA, ethylenediamine-
R. Mackay).metastasis, and is involved in the down-regulation of immunolog-
ical surveillance [12–14]. Originally identiﬁed as a promoter of
metastatic behaviour in Ras-transfected murine ﬁbroblasts [15],
MMP-9 is expressed by malignant tumour cells, tumour-associated
stroma and inﬂammatory leucocytes [1–4,16]. It is secreted as an
inactive, O-glycosylated, 92 kDa zymogen comprised of a N-termi-
nal pro-peptide, a zinc-binding catalytic site and a carboxyl termi-
nal hemopexin-like domain, and is activated either by allosteric
perturbation, oxidation or proteolytic processing by serine prote-
ases such as chymotrypsin, trypsin, cathepsin G and urokinase or
by other MMPs [7,8,12,17]. Upon activation MMP-9 is subject to
autocatalytic processing, which optimises activity prior to inacti-
vating the enzyme [7,8,18].
MMP-9 activity is also regulated by its own hemopexin domain,
which is involved in MMP-9 dimerization, interaction with tissue
inhibitor of metalloproteinase (TIMP)-1 and bioavailability by
binding cell surface LRP1, LRP2 and Ku [19–22]. In puriﬁed recom-
binant form, the MMP-9 hemopexin domain acts as a MMP-9
antagonist [23]; inhibits tumour xenograft growth, invasion, angi-
ogenesis and metastasis; and also inhibits metastatic bone disease
and destructive bone pathology [24–27]. The hemopexin domain
is, therefore, considered a novel therapeutic agent for potential fu-
ture use in MMP-9 dependent pathology. A signiﬁcant drawback of
current MMP-9 inhibitors is, however, reversibility and capacity tolsevier B.V. All rights reserved.
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elimination. This raises the possibility of MMP-9 re-activation
upon inhibitor removal, making the irreversible inhibition of
MMP-9 a preferable therapeutic goal.
Bisphosphonates are well tolerated divalent cation binding
drugs that exhibit direct MMP inhibitory activity, reduce MMP-9
expression and are currently employed to treat Paget’s bone dis-
ease, osteoporosis, myeloma and metastatic bone disease, primar-
ily due to inhibitory effects upon osteoclast function and bone
resorption [28–37]. In this study, we provide novel important
information concerning the bisphosphonate sodium Alendronate
that provides a novel rational for its potential use in MMP-9-
dependent pathology. We report that, in addition to direct MMP-
9 inhibition, Alendronate promotes rapid plasmin-mediated
irreversible MMP-9 inactivation by exposing cryptic plasmin-deg-
radation sites within the MMP-9 catalytic domain, the plasmin-
mediated degradation of which inactivates the MMP-9 catalytic
site, in addition to generating an inhibitory MMP-9 hemopexin
domain fragment.
2. Materials and methods
2.1. Cells and reagents
Mammalian recombinant TIMP-1-free 92 kDa human pro-
MMP-9 was purchased from Calbiochem (Cambridge MA) and
exhibited >95% purity by silver stained SDS–PAGE and did not con-
tain TIMP-1, as judged by Western blot. Recombinant human
28 kDa TIMP-1 was purchased from Calbiochem and exhibited
>95% purity by silver-stained SDS–PAGE. Puriﬁed human 66 kDa
plasmin (speciﬁc activity against D-Val-Leu-Lys-P-Nitroanilide of
2 U/mg) was purchased from Sigma–Aldrich (St Louis, MO). Human
MMP-9/TIMP-1 complexes were puriﬁed by gelatin-Sepharose
afﬁnity chromatography from 72 h MDA-MB-231 breast carcinoma
cell serum-free conditioned medium, as previously described
[38,39]. MMP-9/TIMP-1 complexes exhibited an approximate 1:1
molecular stoichiometry, as judged by silver stained SDS–PAGE
and Western blot. Puriﬁed bacterial recombinant human MMP-9
catalytic domain was purchased from Anaspec (Fremont, CA).
Aminophenylmercuric acetate (APMA), ethylenediaminetetraace-
tic acid (EDTA), bovine type I gelatin and a2-macroglobulin were
purchased from Sigma–Aldrich (St Louis, MO). 3H-labelled rat-tail
type I collagen was purchased from Amersham (Bedford UK). The
anti-MMP-9 hemopexin domain antibody was produced by inocu-
lating New Zealand White rabbits with puriﬁed recombinant hu-
man MMP-9 hemopexin domain (amino acids 536–704), as
previously described [40]. The anti-human MMP-9 catalytic-site
antibody, raised against recombinant MMP-9 catalytic domain,
was purchased from Millipore Inc (Milan, IT). Sodium Alendronate
was kindly provided by Merck, Sharp and Dohme (Rome, IT).
2.2. Gelatinase assays
Assays were performed using heat denatured (30 min 60 C)
rat-tail type I collagen, as previously described [41]. Brieﬂy, reac-
tions containing TIMP-free MMP-9, pre-incubated with either:
plasmin alone; plasmin plus Alendronate, plasmin plus EDTA or
APMA, at the concentrations and for the times indicated, were sub-
sequently incubated with 3H-gelatin (3000 cpm per assay) for 24 h
at 37 C in a buffer containing 0.1 M Tris, 0.2 M NaCl and 1 mM
CaCl2 [pH 8.0] and plasmin inhibitors leupeptin (0.5 lg/ml),
aprotinin (2 lg/ml) and PMSF (1 mM). Following incubation, un-
degraded material was precipitated with 10%TCA/0.5%TA for
30 min at 4 C, precipitates removed by centrifugation at 5000g
and degraded gelatin in supernatants counted in a b-liquid scintil-
lation counter (Beckman model LS 5000TD).2.3. Substrate gel electrophoresis
Regular gelatin and reverse zymograms were prepared, as pre-
viously described [38]. Brieﬂy, samples were subjected to regular
SDS–PAGE under non-reducing conditions in gels co-polymerised
with either 0.1% gelatin for regular zymograms or 0.1% gelatin plus
100 ng/ml of MMP-9 for reverse zymograms. After electrophoresis,
gels were washed in 2% Triton X-100, rinsed in water and incu-
bated in 50 mM Tris, 0.2 M NaCl and 5 mM CaCl2 containing
1 mM PMSF, 0.5 lg/ml leupeptin and 2 lg/ml of Aprotinin to inhi-
bit plasmin within reactions. MMP-9 and MMP-9-inhibitor
activities were visualised following staining and destaining in Coo-
massie blue.
2.4. Western blots
Samples separated by regular reducing SDS–PAGE were trans-
ferred electrophoretically to nitrocellulose (Hybond C-extra,
Amersham, Bucks, UK). Non-speciﬁc protein binding sites on mem-
branes were blocked by 5% non-fat milk in PBS. Membranes were
then incubated with primary antibody diluted in blocking solution
and subsequently with horseradish peroxidase-conjugated second-
ary antibody diluted in blocking solution. Immunoreactivity was
demonstrated by chemiluminescence reaction (Amersham) and
immunoreactive bands were visualised on XAR-5 ﬁlm (Kodak,
Rochester, NY). Molecular weights were approximated by
comparison to pre-stained m.w. standards (Bio-Rad) using Molec-
ular Analyst™/PC for the Bio-Rad Model GS-670 Imaging Densi-
tometer. Antibody speciﬁcity was conﬁrmed by comparison with
pre-immune IgG preparations.
2.5. Statistical analysis
The Student’s t test was used for statistical comparison of data.
A comparison of means giving t values with associated probabili-
ties of difference 60.05 was considered to be statistically
signiﬁcant.3. Results
3.1. In contrast to APMA, plasmin does not directly activate proMMP-9
The incubation of TIMP-free proMMP-9 (100 ng) with APMA
(1 mM) resulted in MMP-9 activation and the degradation of
2800 ± 180 of the 3000 cpm 3H-gelatin used in solution phase as-
say (Fig. 1A, the gelatinolytic activity of APMA activated MMP-9
is represented arbitrarily as 100%). The gelatinolytic activity of
APMA-activated MMP-9 was completely inhibited by co-incuba-
tion with either recombinant TIMP-1 (10 lg/ml), EDTA (1 mM) or
Sodium Alendronate, which at a concentration of 10 nM inhibited
gelatinolytic activity by 12 ± 15% (NS, n = 12), by 55 ± 8.5%
(p < 0.05; n = 12) at a concentration of 100 nM and by 98.5 ±
18.3% (p < 0.001; n = 12) at a concentration of 1 lM (Fig. 1A).
Alendronate also inhibited the gelatinolytic activity of SDS-
activated MMP-9 in a gelatin zymogram-strip assay, following
incubation of renatured zymogram strips containing 100 ng of
TIMP-free proMMP-9 for 16 h with increasing concentrations of
Alendronate (Fig. 1B). Alendronate exhibited in an inhibitory IC50
concentration of approximately 100 nM in both solution phase
and zymogram-strip assays.
Gelatin zymography revealed that APMA had induced the
conversion of TIMP-free 92 kDa proMMP-9 to 83 kDa and 68 kDa
species (Fig. 1C), conﬁrming a previous report [18]. Both EDTA
(1 mM) and Alendronate (1 mM) inhibited APMA-induced proM-
MP-9 processing to 83 kDa and 68 kDa species, consistent with
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Fig. 1. (A) Histogram demonstrating the percentage of 3H gelatin degraded by (1) 100 ng TIMP-1-free proMMP-9; (2) 100 ng APMA-activated (1 mM) TIMP-1-free MMP-9; (3)
100 ng APMA-activated (1 mM) TIMP-1-free MMP-9 plus 10 lM Alendronate; (4) 100 ng APMA-activated (1 mM) MMP-9 plus 100 lM Alendronate; (5) 100 ng APMA-
activated (1 mM) TIMP-1-free MMP-9 plus 1 mM Alendronate; (6) 100 ng APMA-activated (1 mM) MMP-9 plus 10 mM Alendronate and (7) 100 ng APMA-activated (1 mM)
TIMP-1-free MMP-9 plus 1 mM EDTA. Results are expressed as the mean ± s.d. percentage difference with respect to APMA-activated MMP-9 controls (100%) in duplicate
assays each performed using six samples per group. (B) Representative gelatin strip assays demonstrating gelatinolytic activity of 100 ng of SDS-activated TIMP-1-free MMP-9
incubated for 16 h at 37 C in (1) collagenase buffer alone; (2) collagenase buffer containing 10 lM Alendronate; (3) collagenase buffer containing 100 lM Alendronate; (4)
collagenase buffer containing 1 mM Alendronate and (5) collagenase buffer containing 10 mM Alendronate. (C) Representative gelatin zymograms demonstrating the effect of
incubating 100 ng TIMP-1-free proMMP-9 with 1 mM APMA for the times indicated. (D) Representative gelatin zymogram demonstrating the gelatinolytic activity of 100 ng
TIMP-1-free proMMP-9: (1) alone; (2) following 6 h pre-incubation with 1 mM APMA; (3) following 6 h incubation with 1 mM APMA in the presence of 1 mM Alendronate;
and (4) following 6 h incubation with 1 mM APMA in the presence of 1 mM EDTA. (E) Representative Western blots demonstrating anti-MMP-9 hemopexin domain-
immunoreactivity of 100 ng TIMP-1-free proMMP-9 incubated for the times indicated with 1 mM APMA (left panel) and anti-MMP-9 catalytic domain immunoreactivity of
100 ng TIMP-1-free proMMP-9 incubated alone (con) or for 3 h with 1 mM APMA (right panel).
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and 4). In Western blots, 92 kDa proMMP-9 and 83 kDa APMA-acti-
vated MMP-9 but not 68 kDa APMA-activated MMP-9 species were
recognised by anti-MMP-9 hemopexin–domain antibody (Fig. 1E,
right panel). Over a 48 h activation time course, >95% of the
APMA-activated 83 kDa MMP-9 species was lost due to continuous
autocatalytic processing (Fig. 1E). Both the APMA-activated 83 kDa
and 68 kDa MMP-9 species were recognised by anti-catalytic do-
main MMP-9 antibody (Fig. 1E, left panel).
In contrast to the effect of APMA, incubation of proMMP-9
(100 ng) with puriﬁed human plasmin (5 lg/ml – 0.01 U) for times
up to 24 h prior to 3H-gelatinase assay under plasmin inhibitory
conditions, did not activate MMP-9 to degrade gelatin (Fig. 2A).Plasmin did, however, induce the low-level conversion of 92 kDa
proMMP-9 to a single 82 kDa species, detected by gelatin zymogra-
phy (Fig. 2B). This species was recognised in Western blots by both
anti-MMP-9 hemopexin–domain and catalytic-domain antibodies
(Fig. 2C, data displayed for anti-hemopexin domain antibody only).
Plasmin generation of the 82 kDa MMP-9 species was inhibited by
leupeptin (0.5 lg/ml) but not by TIMP-1 (10 lg/ml) in gelatin
zymograms (Fig. 2D). The incubation of reactions containing plas-
min-generated 82 kDa MMP-9 with fourfold molar excess a2-mac-
roglobulin for 1 h did not result in a2-macroglobulin binding of
this species, as judged by gelatin zymography (Fig. 2E). In contrast
to the 83 kDa APMA-activated MMP-9 species, the 82 kDa MMP-9
species generated by plasmin was stable, continued to accumulate
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Fig. 2. (A) Histogram demonstrating the percentage of 3H gelatin degraded by 100 ng of TIMP-1 free proMMP-9 alone (con) or following pre-incubation with plasmin (5 lg/
ml) for the times indicated in hours, prior to 3H gelatinase assay under plasmin inhibitory conditions. (B) Representative gelatin zymogram demonstrating the effect of
incubating 100 ng of TIMP-1-free proMMP-9 with plasmin (5 lg/ml) for the times indicated. (C) Representative Western blot demonstrating anti-MMP-9 hemopexin domain
immunoreactivity of 100 ng TIMP-1-free proMMP-9 incubated with plasmin (5 lg/ml) for the times indicated. (D) Representative gelatin zymogram demonstrating the
gelatinolytic of 100 ng TIMP-1-free pro-MMP-9: (1) alone; (2) pre-incubated for 3 h with plasmin (5 lg/ml); (3) pre-incubated for 3 h with plasmin (5 lg/ml) plus TIMP-1
(10 lg/ml); and (4) pre-incubated for 3 h with plasmin (5 lg/ml) plus leupeptin (0.5 lg/ml). (E) Representative gelatin zymogram demonstrating the gelatinolytic activity of
100 ng TIMP-1-free pro-MMP-9: (1) alone; (2) pre-incubated for 4 h with plasmin (5 lg/ml); and (3) pre-incubated for 3 h with plasmin (5 lg/ml) followed by 1 h with
fourfold molar excess a2-macroglobulin.
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period (Fig. 2B and C).
3.2. Alendronate and EDTA promote plasmin-mediated degradation of
pro-MMP-9 and APMA-activated MMP-9
Unexpectedly, the co-incubation of 100 ng proMMP-9 with
plasmin (5 lg/ml) in the presence of either 1 mM EDTA or 1 mM
Alendronate resulted in complete degradation of proMMP-9 within
3 h to a major 49 kDa fragment recognised by anti-MMP-9 hemo-
pexin–domain but not catalytic-domain antibody (Fig. 3A right
and left panels), and to 26 kDa and 8 kDa species recognised by
anti-MMP-9 catalytic-domain but not hemopexin–domain anti-
body in Western blots (Fig. 3B). This degradation was dose-depen-
dent, with 10 lM Alendronate promoting little, 100 lM
Alendronate partial and 1 mM Alendronate complete plasmin-
mediated degradation of 100 ng proMMP-9, within 3 h (Fig. 3A,
lanes 5 and 6). Promotion of plasmin-mediated MMP-9 degrada-
tion by Alendronate and EDTA resulted in the complete loss of
MMP-9 activity in zymograms (Fig. 3C, lanes 3 and 4). This effect
was inhibited by leupeptin (0.5 lg/ml) but not by recombinant
TIMP-1 (10 lg/ml) (Fig. 3D, lanes 4 and 5). MMP-9 pre-activated
by 3 h incubation with 1 mM APMA was also completely degraded
by plasmin (5 lg/ml) in the presence of 1 mM Alendronate or
1 mM EDTA to inactive 26 kDa and 8 kDa catalytic-domain species
(Fig. 4A, lanes 3 and 4). Under these conditions, however, degrada-tion did not generate the 49 kDa hemopexin domain MMP-9 frag-
ment, which was detected using proMMP-9. The degradation of
APMA-activated MMP-9 by plasmin in the presence of Alendronate
or EDTA resulted in the complete loss of MMP-9 gelatinolytic
activity in zymograms (Fig. 4B, lanes 6 and 7). In the absence of
plasmin, both 1 mM Alendronate and 1 mM EDTA inhibited auto-
catalytic processing of MMP-9 pre-activated by APMA (Fig. 4B,
lanes 2 and 4).
Recombinant 37 kDa human MMP-9 catalytic domain (100 ng)
was completely degraded by plasmin (5 lg/ml) within 3 h to
26 kDa, 17 kDa and 8 kDa species recognised by anti-MMP-9 cata-
lytic domain antibody, both in the presence and absence of 1 mM
EDTA, in association with complete loss of activity in gelatin
zymograms. EDTA alone did not alter recombinant MMP-9 cata-
lytic domain (Fig. 4C and D).
Puriﬁed proMMP-9 in TIMP-1-complexed form (150 ng)
(Fig. 5A) exhibited low level conversion from 92 kDa to 82 kDa
when incubated with plasmin (5 lg/ml) for 3 h (Fig. 5B), and was
degraded by plasmin (5 lg/ml) in the presence of 1 mM Alendro-
nate or 1 mM EDTA to the 49 kDa hemopexin–domain fragment,
in the absence of changes in 28 kDa TIMP-1 immunoreactivity in
Western blots (Fig. 5C). This was associated with the complete loss
of MMP-9 activity in gelatin zymograms (Fig. 5B, lanes 3 and 4).
MDA-MB-231 breast cancer cells, characterised by constitutive
MMP-9 and plasminogen activator expression [38,39], were cul-
tured for 72 h in serum-free conditions prior to being incubated
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Fig. 3. (A) Representative Western blots demonstrating anti-MMP-9 hemopexin–domain immunoreactivity of 100 ng TIMP-1-free pro-MMP-9: (1) alone; (2) pre-incubated
for 3 h with plasmin (5 lg/ml); (3) pre-incubated for 3 h with plasmin (5 lg/ml) plus 1 mM EDTA; (4) pre-incubated for 3 h with plasmin (5 lg/ml) plus 10 lM Alendronate;
(5) pre-incubated for 3 h with plasmin (5 lg/ml) plus 10 lM Alendronate; and (6) pre-incubated for 3 h with plasmin (5 lg/ml) plus 1 mM Alendronate. (B) Representative
Western blots demonstrating anti-MMP-9 catalytic-domain immunoreactivity of 100 ng TIMP-1-free pro-MMP-9: (1) alone; (2) pre-incubated for 3 h with plasmin (5 lg/ml);
(3) pre-incubated for 3 h with plasmin (5 lg/ml) plus 1 mM EDTA; (4) pre-incubated for 3 h with plasmin (5 lg/ml) plus 1 mM Alendronate. (C) Representative gelatin
zymogram demonstrating the gelatinolytic of 100 ng TIMP-1-free pro-MMP-9: (1) alone; (2) pre-incubated for 3 h with plasmin (5 lg/ml); (3) pre-incubated for 3 h with
plasmin (5 lg/ml) plus 1 mM EDTA; (4) pre-incubated for 3 h with plasmin (5 lg/ml) plus 1 mM Alendronate. (D) Representative gelatin zymogram demonstrating the
gelatinolytic of 100 ng TIMP-1-free pro-MMP-9: (1) alone; (2) pre-incubated for 3 h with plasmin (5 lg/ml); (3) pre-incubated for 3 h with plasmin (5 lg/ml) plus 1 mM
Alendronate; (4) pre-incubated for 3 h with plasmin (5 lg/ml) plus 1 mM Alendronate plus leupeptin (0.5 lg/ml); (5) pre-incubated for 3 h with plasmin (5 lg/ml) plus 1 mM
Alendronate plus TIMP-1 (10 lg/ml).
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absence of 1 mM Alendronate or 1 mM EDTA. Under these condi-
tions, MDA-MB-231 cells activated exogenous plasminogen, which
in the absence of Alendronate or EDTA resulted in plasmin-medi-
ated endogenous proMMP-9 conversion from 92 kDa to 82 kDa,
and in the presence of 1 mM Alendronate or 1 mM EDTA resulted
in the complete elimination of MMP-9 activity, associated with
complete degradation of proMMP-9 to the 49 kDa hemopexin–do-
main fragment (Fig. 5D and E, lanes 3 and 4). Neither EDTA nor
Alendronate alone altered endogenous proMMP-9 secreted by
MDA-MB-231 cells in gelatin zymograms or Western blots (data
not shown).
Puriﬁed TIMP-1-free proMMP-9 was not processed by 6 h incu-
bation with either puriﬁed human glu-plasminogen (10 lg/ml)
alone; puriﬁed human uPA (1 lg/ml) alone; puriﬁed glu-plasmin-
ogen (10 lg/ml) plus 1 mM EDTA; puriﬁed glu-plasminogen
(10 lg/ml) plus 1 mM Alendronate; puriﬁed uPA (1 lg/ml) plus
EDTA or puriﬁed uPA (1 lg/ml) plus 1 mM Alendronate (data not
shown).
3.3. Plasmin generated MMP-9 hemopexin–domain inhibits the
activity of MMP-9
Reverse MMP-9 zymography detected MMP-9 inhibitory activ-
ity of approximately 45 kDa in reactions containing MMP-9 degra-
dation products, resulting from 3 h incubation of proMMP-9 with
plasmin (5 lg/ml; 0.01 U) in the presence of 1 mM EDTA or
1 mM Alendronate (Fig. 6, lanes 2 and 5) but not in reactions con-
taining proMMP-9 alone or proMMP-9 incubated with plasmin in
the absence of Alendronate or EDTA (Fig. 6, lanes 1 and 3). Inhibi-tory activity was conﬁrmed by the complete absence of equivalent
bands in the same samples in Coomassie blue-stained regular non-
reducing SDS–PAGE gels (not shown).4. Discussion
In this study, we report that the divalent cation-binding bis-
phosphonate Alendronate and the divalent cation-chelator EDTA
not only directly inhibit MMP-9 but also promote rapid plasmin-
mediated irreversible inactivation of pro-form and active MMP-9.
This results from divalent cation chelation-mediated exposure of
cryptic plasmin degradation sites within the MMP-9 catalytic do-
main to plasmin-mediated inactivation by degradation, and in
the case of proMMP-9 also generation of an inhibitory MMP-9
hemopexin–domain fragment, deﬁning a novel mechanism for
irreversible MMP-9 inhibition.
APMA induced autocatalytic activation of TIMP-1-free proMMP-
9 to 82 kDa and 68 kDa species, conﬁrming a previous report [18].
In contrast, puriﬁed human plasmin did not activate TIMP-1 free
proMMP-9, despite low level 92 kDa proMMP-9 conversion to a
single 82 kDa MMP-9 species. This species exhibited activity in gel-
atin zymograms consistent with an intact catalytic domain but did
not bind a2-macroglobulin, which binds activated MMP-9 forms
[42,43], indicating that this species is inactive. In support of this
and in contrast to 83 kDa APMA-activated MMP-9 that exhibits
time-dependent autocatalytic elimination associated with the gen-
eration of additional species [this study and 18], the 82kda MMP-9
species generated by plasmin was stable, accumulated over 48 h
and did not precede the generation of additional autocatalytic
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Fig. 4. (A) Representative Western blots demonstrating anti-MMP-9 catalytic-domain immunoreactivity of 100 ng TIMP-1-free pro-MMP-9: (1) alone; (2) pre-incubated for
3 h with 1 mM APMA; (3) pre-incubated for 3 h with 1 mM APMA followed by 3 h with plasmin (5 lg/ml) plus 1 mM EDTA; (4) pre-incubated for 3 h with 1 mM APMA
followed by 3 h with plasmin (5 lg/ml) plus 1 mM Alendronate. (B) Representative gelatin zymogram, demonstrating gelatinolytic activity of 100 ng TIMP-1-free proMMP-9:
(1) alone; (2) pre-incubated for 3 h with 1 mM APMA then for 3 h with 1 mM EDTA; (3) pre-incubated for 6 h with 1 mM APMA; (4) pre-incubated for 3 h with 1 mM APMA
then for 3 h with 1 mM Alendronate; (5) pre-incubated for 3 h with 1 mM APMA then for 3 h with plasmin (5 lg/ml); (6) pre-incubated for 3 h with 1 mM APMA then for 3 h
with plasmin (5 lg/ml) plus 1 mM EDTA; and (7) pre-incubated for 3 h with 1 mM APMA then for 3 h with plasmin (5 lg/ml) and 1 mM Alendronate. (C) Representative
Western Blot, demonstrating anti-MMP-9 catalytic-domain immunoreactivity of 100 ng puriﬁed recombinant MMP-9 catalytic domain; (1) alone; (2) pre-incubated for 3 h
with 1 mM EDTA; (3) pre-incubated for 3 h with plasmin (5 lg/ml); and (4) pre-incubated for 3 h with plasmin (5 lg/ml) plus 1 mM EDTA. (D) Representative Gelatin
zymogram, demonstrating the gelatinolytic activity of 100 ng puriﬁed bacterial recombinant human MMP-9 catalytic domain; (1) alone; (2) pre-incubated for 3 h with 1 mM
EDTA; (3) pre-incubated for 3 h with plasmin (5 lg/ml); and (4) pre-incubated for 3 h with plasmin (5 lg/ml) plus 1 mM EDTA.
A.R. Farina et al. / FEBS Letters 586 (2012) 2366–2374 2371MMP-9 species. Furthermore, EDTA and Alendronate but not leu-
peptin inhibited generation of the 83 kDa MMP-9 by APMA and
vice versa for the 82 kDa MMP-9 species generated by plasmin,
conﬁrming that the former depends upon autocatalytic processing
and the latter depends upon plasmin activity and not autocatalysis.
These data support some [44,45] but not all reports [46], that hu-
man plasmin does not directly activate human proMMP-9 and sug-
gests that the inactive 82 kDa MMP-9 species generated by
plasmin may represent a novel MMP-9 pro-form similar to that re-
ported to be expressed by human leukaemia cells [47]. This pre-
sumably indicates that 82 kDa proMMP-9 generated by plasmin
must contain the cysteine-switch sequence of the pro-peptide do-
main and must, therefore, result either from carboxyl terminal
degradation or amino terminal degradation upstream of the cys-
teine switch [9].
Consistent with previous reports that bisphosphonates directly
inhibit MMP activity, Alendronate directly inhibited the activity of
both APMA-activated and SDS-activated MMP-9 in a dose-depen-
dent manner, with an approximate inhibitory IC50 of 100 lM. This
adds MMP-9 to other MMPs directly inhibited by bisphosphonates
and adds Alendronate to other MMP-inhibitory bisphosphonates
[28,30–32]. Consistent with this, Alendronate like EDTA, also inhib-
ited APMA-induced autocatalytic MMP-9 processing.
Unexpectedly, plasmin in the presence of Alendronate or EDTA
rapidly degraded both latent and APMA-activated MMP-9 to inac-
tive 26 kDa and 8 kDa catalytic-domain fragments and, in the case
of proMMP-9 generated a 49 kDa hemopexin–domain fragment,
indicating that these divalent cation chelators expose crypticplasmin-degradation sites within native MMP-9. Under these con-
ditions, MMP-9 degradation resulted in the eventual complete and
irreversible loss of MMP-9 activity, in the absence of even transient
MMP-9 activation. Under these conditions, plasmin did not de-
grade APMA-activated MMP-9 to the 49 kDa hemopexin domain
fragment, since the hemopexin domain of MMP-9 is eliminated
by autocatalysis upon APMA-activation [18]. In contrast to pro-
form and APMA activated-MMP-9, plasmin degraded and inacti-
vated puriﬁed bacterially expressed recombinant human MMP-9
catalytic-domain both in the presence and absence of divalent cat-
ion chelators to 26 kDa, 17 kDa and 8 kDa fragments. This conﬁrms
the presence of at least two plasmin degradation sites within the
MMP-9 catalytic domain. The fact that these sites do not appear
to be cryptic in puriﬁed bacterial recombinant human MMP-9 cat-
alytic domain may be the result either of the bacterial expression
and puriﬁcation process or may indicate that these sites are ren-
dered cryptic in the full length native protein by divalent cation
regulated structures that lie outside of the catalytic domain, rather
than catalytic domain divalent cations [48,49]. In any case, these
degradation sites lie within the catalytic-domain amino acid se-
quence 107–425, downstream of the pro-peptide sequence re-
moved from AMPA-activated MMP-9 by cleavage at amino acids
A74 and M75 [9] and not present in recombinant MMP-9 catalytic
domain. Furthermore, it is clear that degradation of these sites
must separate the catalytic active site from the catalytic zinc-bind-
ing site, since the presence of both is required for MMP-9 catalytic
activity and the deletion of the catalytic Zn2+ binding site inacti-
vates recombinant MMP-9 catalytic-domain. Within this sequence,
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Fig. 5. (A) Silver stained SDS–PAGE (left panel) plus Western blots (middle and right panels) demonstrating relative MMP-9 and TIMP-1 levels in 150 ng MMP-9/TIMP-1
complexes puriﬁed from human MDA-MB-231 breast cancer cells; (B) Representative gelatin zymogram, demonstrating gelatinolytic activity of 150 ng puriﬁed MMP-9/
TIMP-1 complexes: (1) alone; (2) pre-incubated for 3 h with plasmin (5 lg/ml); (3) pre-incubated for 3 h with plasmin (5 lg/ml) plus 1 mM EDTA; (4) pre-incubated for 3 h
with plasmin (5 lg/ml) plus 1 mM Alendronate. (C) Representative Western blots demonstrating anti-MMP-9 hemopexin–domain (upper panel) and TIMP-1 (lower panel)
immunoreactivity of 150 ng puriﬁed MMP-9/TIMP-1 complexes: (1) alone; (2) pre-incubated for 3 h with plasmin (5 lg/ml); (3) pre-incubated for 3 h with plasmin (5 lg/ml)
plus 1 mM EDTA; and (4) pre-incubated for 3 h with plasmin (5 lg/ml) plus 1 mM Alendronate. (D) Representative gelatin zymogram, demonstrating gelatinolytic activity of
endogenous proMMP-9 in unconcentrated serum-free 72 h MDA-MB-231 conditioned medium: (1) alone; (2) pre-incubated for 6 h with exogenous plasminogen (10 lg/ml);
(3) pre-incubated for 6 h with exogenous plasminogen (10 lg/ml) plus 1 mM EDTA; (4) pre-incubated for 6 h with exogenous plasminogen (10 lg/ml) plus 1 mM
Alendronate. (E) Representative Western blot demonstrating anti-MMP-9 hemopexin–domain immunoreactivity of endogenous proMMP-9 in unconcentrated serum-free
72 h MDA-MB-231 conditioned medium: (1) alone; (2) from cultures pre-incubated for 6 h with exogenous plasminogen (10 lg/ml); (3) cultures pre-incubated for 6 h with
exogenous plasminogen (10 lg/ml) plus 1 mM EDTA; and (4) cultures pre-incubated for 6 h with exogenous plasminogen (10 lg/ml) plus 1 mM Alendronate.
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site and do not depend upon divalent cations for their conforma-tion. This suggests that plasmin degradation site(s) exposed within
the catalytic domain by divalent cation chelators may lie outside
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Fig. 6. Reverse MMP-9 zymogram demonstrating (1) no MMP-9 inhibitory activity
in a reaction containing 100 ng TIMP-1-free proMMP-9 pre-incubated for 3 h with
1 mM EDTA alone; (2) 45 kDa MMP-9 inhibitory activity in a reaction containing
TIMP-1-free pro-MMP-9 pre-incubated for 3 h with plasmin (5 lg/ml) plus 1 mM
EDTA; (3) No MMP-9 inhibitory activity in a reaction containing TIMP-1-free pro-
MMP-9 pre-incubated for 3 h with plasmin (5 lg/ml) alone; (4) No MMP-9
inhibitory activity in a reaction containing 100 ng TIMP-1-free proMMP-9 pre-
incubated for 3 h with 1 mM Alendronate alone; and (5) 45 kDa MMP-9 inhibitory
activity in a reaction containing 100 ng TIMP-1-free proMMP-9 pre-incubated for
3 h with plasmin (5 lg/ml) plus 1 mM Alendronate.
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repeats plus the functional Zn1 binding site; the active site plus
FN2 repeats from the functional Zn1 binding site, or both [48–50].
The effects observed with MMP-9 may also extend to MMP-2,
which exhibits close catalytic and hemopexin–domain structural
and functional similarity to MMP-9 [48], and is degraded by plas-
min in osteoblast cultures in the presence of bisphosphonates [51].
In contrast to the MMP-9 catalytic domain, hemopexin–domain
structure does not depend upon divalent cations [48,49], helping to
explain why plasmin in the presence of Alendronate or EDTA gen-
erated a 49 kDa hemopexin–domain fragment from proMMP-9.
MMP-3 also degrades MMP-9 to a 50 kDa hemopexin–domain
fragment by cleaving amino acid 429 at the sequence EPE within
the linker region that divides the proline-rich O-glycosylation-do-
main upstream of the hemopexin domain from the catalytic Zn2+
binding site [18]. The 49 kDa hemopexin–domain fragment gener-
ated by plasmin is likely, therefore, to result from the exposure of a
cryptic plasmin degradation site close to this region.
Reverse MMP-9 zymography detected 45 kDa MMP-9 inhibi-
tory activity in reactions containing MMP-9, plasmin and either
Alendronate or EDTA, conﬁrming the presence of MMP-9 inhibi-
tory activity, following Alendronate and EDTA removal. This sup-
ports and extends a previous report, that recombinant human
MMP-9 hemopexin–domain acts as an MMP-9 antagonist [23]
and characterises a biological function for the MMP-9 fragment
generated by plasmin in this study. Recombinant MMP-9 hemo-
pexin domain has also been reported to inhibit tumour cell inva-
sion, angiogenesis, xenograft growth, metastasis, metastatic bone
disease and destructive bone pathology [24–28].
In addition to its effects upon puriﬁed pro-MMP-9, APMA-acti-
vated MMP-9 and recombinant MMP-9 catalytic domain, plasmin
in the presence of Alendronate or EDTA also inactivated
proMMP-9 in the presence of molar TIMP-1 excess and in TIMP-
1-complexed form indicating that TIMP-1 interaction with the
hemopexin–domain [20] does not protect proMMP-9 from
plasmin-mediated inactivation by degradation upon cryptic degra-
dation site exposure. Furthermore, in a MDA-MB-231 breast cancer
cell model characterised by constitutive proMMP-9 and plasmino-
gen activator expression [38,39], activation of exogenous plasmin-
ogen only in the presence of Alendronate or EDTA resulted in
proMMP-9 degradation to the 49 kDa hemopexin–domain frag-
ment, associated with complete loss of MMP-9 gelatinolytic activ-
ity without evidence of TIMP-1 degradation. The eventual
irreversible plasmin-mediated inactivation of MMP-9 by degrada-
tion in the presence of divalent cation chelators occurred in the ab-sence of even transient MMP-9 activation, attesting to the
incapacity of plasmin to activate proMMP-9 and the direct MMP-
9 inhibitory activity of Alendronate and EDTA, which is exempliﬁed
by the complete direct inhibition, associated with complete
plasmin-mediated degradation of 100 ng MMP-9 by 1 mM
Alendronate.
In conclusion, our data provide a novel rational for therapeutic
use of Alendronate in MMP-9-dependent pathologies characterised
by plasmin activation, both as a direct MMP-9 inhibitor and pro-
moter of irreversible plasmin-mediated inactivation of MMP-9 in
zymogen, activated, TIMP-free and TIMP-complexed forms, in
addition to providing a novel method for the irreversible inactiva-
tion of MMP-9 and production of biologically active MMP-9 hemo-
pexin–domain.
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